期刊文献+

TTC及FTC方案新辅助化疗治疗乳腺癌的疗效分析 被引量:2

Study on the efficacy of neoadjuvant chemotherapy with TTC and FTC regimens for the treatment of breast cancer
原文传递
导出
摘要 目的比较新辅助化疗方案TTC及FTC治疗乳腺癌的疗效。方法收集325例乳腺癌新辅助化疗患者的资料,其中TTC方案138例、FTC方案187例,并采用免疫组织化学法检测所有患者化疗前活组织检查标本TopoⅡa的表达状况。结果TTC组、FTC组乳腺癌总缓解率(RR)分别为87.7%、67.4%,两组差异有统计学意义(P=0.000);而分层分析显示:在TopoⅡa(-)组,TTC、FTC两组患者RR差异均有统计学意义,而TopoⅡa(+)Her-2(-)组,FTC组为79.4%,TTC组为87.8%,差异无统计学意义(P=0.266);TTC组、FTC组患者的病理完全缓解率分别为13.7%、11.2%,差异无统计学意义(P=0.491)。结论新辅助化疗TTC较FTC方案有较高的缓解率;而对于TopoⅡa(-)患者,应用或联合紫杉类药物治疗可能取得更好的疗效。 Objective To investigate the efficacy of TTC and FTC regimens as neoadjuvant chemotherapy in breast cancer. Methods Collecting clinical data of 325 patients received neoadjuvant chemotherapy with TTC and FTC regimens from June 2004 to April 2008, among them 138 patients received neoadjuvant chemotherapy with TIC regimen in one group, and 187 patients received neoadjuvant chemotherapy with CTF regimen in the other group. The expression of Topo Ⅱ a in specimen of 325 patients before neoadjuvant chemotherapy were detected by immunohistochemical method. Results Among the 325 cases of neoadjuvant chemotherapy, the overall response rate (RR) was 87.7 % in TIC arm and 67.4 % in FTC arm (P = 0.000) , but in the group of Topo Ⅱ a(+) Her-2(-), the overall response rate (RR) was 87.8 % in TTC arm and 79.4 % in FTC arm (P =0.266), and in the groups of Topo Ⅱ a(-), there was statistical significance; the pathologic complete response rate (pCR) was 13.7 % in TTC arm and 11.2 % in CTF arm (P =0.491). Conclusion TTC regimen is superior to FTC regimen in the response rate of neoadjuvant chemotherapy, but patients with negative expression of Topo Ⅱ a may get more benefits from neoadjuvant taxane and anthracycline chemotherapy.
出处 《肿瘤研究与临床》 CAS 2009年第7期472-474,共3页 Cancer Research and Clinic
关键词 乳腺肿瘤 拓扑异构酶Ⅱ a TTC FTC 抗肿瘤联合化疗方案 Breast neoplasms Chemotherapy Topoisomerase Ⅱa Trc FTC Antineoplastic combined chemotherapy protocols
  • 相关文献

参考文献14

  • 1Hirano A,Shimizu T,Imamura H,et al.The combination of epirubicin plus docetsxel as neoadjuvant chemotherapy in locally advanced breast cancer.Antieancer Res,2006,26:581-584.
  • 2Bear HD,Anderson S,Brown A,et al.The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide:preliminary results from National Surgical Adjuvant Breast and Bowel Project Protecol B-27.J Clin Oncol,2003,21:4165-4174.
  • 3Gianni L,Baselga J,Eiermann W,et al.First report of the European Cooperative Trial in Operable breast cancer (ECTO):effects of primary systemic therapy (PST) on local-reginal disease.Proc Amsoc Clin Oncol,2002,21:132.
  • 4Cance WG,Carey LA,Calvo BF,et al.Long-term outcome of neoadjuvant therapy for locally advanced breast carcinoma:effective clinical downstaging allows breast preservation and predicts outstanding local control and survival.Ann Surg,2002,236:295-302; discussion 302-303.
  • 5Jarvinen TA,Kononen J,Pelto-Huikke M,et al.Expression of topoisomerase Ⅱ alpha is associated with rapid cell proliferation,aneuploidy,and c-erbB2 overexpression in breast cancer.Am J Pathol,1996,148:2073-2082.
  • 6Jarvinen TA,Tanner M,Barlund M,et al.Characterization of topoisomersse Ⅱ alpha gene amplification and deletion in breast cancer.Genes Chromosomes Cancer,1999,26:142-150.
  • 7O'Malley FP,Chia S,Shepherd LE,et al.Topoisomerase Ⅱ alpha protein overexpression has predictive utility in a randomized trial comparing CMF to CEF in premenopausal women with node positive breast cancer (NCIC CTG MA.5).Breast Cancer Res Treat,2006,100:S18.
  • 8Durbecq V,Paesmans M,Cardoso F,et al.Topoisomerase-Ⅱ alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent decetaxel.Mol Cancer Tber,2004,3:1207-1214.
  • 9Learn PA,Yeh IT,McNutt M,et al.HER-2/neu expression as a predictor of response to neoadjuvant docetaxel in patients with operable breast carcinoma.Cancer,2005,103:2252-2260.
  • 10Tiezzi DG,Andrade JM,Ribeiro silva A,et al.HER-2,p53,p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination.BMC Cancer,2007,7:36.

同被引文献28

  • 1Kantidze OL, Larovaia OV, Razin SV. Assembly of nuclear matrix-bound protein complexes involved in non-homologous end joining is induced by inhibition DNA topoisomerase Ⅱ. J Cell Physical, 2006, 207: 660-667.
  • 2Perry MC. The chemotherapy source Book. 3th ed. Philadelphia: Lippincott Williams and Wilkins, 2002: 278-289.
  • 3Pusztai L. Current status of prognostic profiling in breast cancer. Oncologist, 2008, 13: 350-360.
  • 4Hajduk M. Topoisomenase H alpha fundamental prognostic factor in breast carcinoma. Pol J Pathol, 2009, 60: 67-75.
  • 5Chell S, Kadi A, Caroline A, et al. Mediators of PGE2 synthesis and signaling downstream of COX-2 represent potential targets for the prevention treatment of colerectal cancer. Biochin Biophys Acta, 2006, 1776: 104-109.
  • 6Liu CH, Chang SH, Narko K, et al. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. Biol Chem, 2001, 276: 18563-18569.
  • 7Denkert C, Winzer K J, Hauptmann S. Prognostic impact of cyclooxygenase-2 in breast cancer. Clin Breast Cancer, 2004, 4: 428-433.
  • 8Ristimaki A, Sivula A, Lundin J. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res, 2002, 62: 632-663.
  • 9Subbrammaiah K, Norton L, Gerald W, et al. 2002. Cyclooxygenase-2 is overexpressed in Her-2 / neu-positive breast cancer. Evidence for involvement of AP-1 and PEA3. J Biol Chem, 2002, 277: 18649-18657.
  • 10Ihemelandu CU, Leffall LD, Dewitty RL, et al. Molecular breast cancer subtypes in premenopausal and postmenopausal Mrican-Ameriean women: age-specific prevalence and survival. J Surg Res, 2007, 143: 109-118.

引证文献2

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部